



Assessment of the burden of malaria and bacteraemia by retrospective molecular diagnosis in febrile illnesses and first-line anti-infectives in Côte d'Ivoire

Bilé Cyrille Hervé Ehounoud, Celia Scherelle Boumbanda Koyo, Landry Doua Bongue, Sébastien Cortaredona, Adèle N'douba Kakou, Djanwai Berenger Konan, Yao Kouassi Patrick, Nadia Amanzougaghene, Jean-David N'guessan, Bernard Davoust, et al.

► To cite this version:

Bilé Cyrille Hervé Ehounoud, Celia Scherelle Boumbanda Koyo, Landry Doua Bongue, Sébastien Cortaredona, Adèle N'douba Kakou, et al.. Assessment of the burden of malaria and bacteraemia by retrospective molecular diagnosis in febrile illnesses and first-line anti-infectives in Côte d'Ivoire. *Travel Medicine and Infectious Disease*, 2021, 43, pp.102105. 10.1016/j.tmaid.2021.102105 . hal-03429328

HAL Id: hal-03429328

<https://amu.hal.science/hal-03429328>

Submitted on 2 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Assessment of the burden of malaria and bacteraemia by retrospective molecular diagnosis in febrile illnesses and first-line anti-infectives in Côte d'Ivoire

Bilé Cyrille Hervé EHOUNOUD^{a,b,c,d,†}, Celia Scherelle BOUMBANDA KOYO^{a,b,e,ff}, Landry DOUA BONGUE^g, Sébastien CORTAREDONA^{a,b}, Adèle N'DOUBA KAKOU^h, Djanwai Berenger KONAN^g, Patrick YAO KOUASSI^c, Nadia AMANZOUGAGHENE^{b,i}, Jean-David N'GUESSAN^c, Bernard DAVOUST^{b,i}, Didier RAOULT^{b,i}, Oleg MEDIANNIKOV^{b,i}, Florence FENOLLAR^{a,b,*}

[†]Equally contributed

^aAix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France

^bIHU-Méditerranée Infection, Marseille, France

^cFélix Houphouët Boigny Université, UFR Biosciences, Côte D'Ivoire

^dInstitut Pierre Richet, Institut National de Santé Publique, Bouaké, Côte d'Ivoire

^eUnité d'Evolution, Epidémiologie et Résistances Parasitaires (UNEEREP), Centre International de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon

^fEcole Doctorale Régionale en Infectiologie Tropicale d'Afrique Centrale, Franceville, Gabon

^gCentre Médico Social Wale, BP 1336 Yamoussoukro, Côte d'Ivoire

^hFaculté de Médecine, Pharmacie et Odonto-Stomatologie, Université Félix Houphouët Boigny, Côte d'Ivoire

ⁱAix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France

*Corresponding author: Florence FENOLLAR (florence.fenollar@univ-amu.fr)

† - Doctor Bilé Cyrille Hervé EHOUNOUD passed away in August 2020

Word abstract count: 248

Word text count: 3,341

Keywords: Fever; Bacteraemia; Malaria; Côte d'Ivoire; *Salmonella enterica*; *Streptococcus pneumoniae*

ABSTRACT

Background: The aetiologies of fever are poorly understood in sub-Saharan Africa. We aimed to assess the burden of malaria and bacteria in Côte d'Ivoire.

Methods: Blood samples from 438 febrile and 346 afebrile people were screened using molecular tools.

Results: *Plasmodium falciparum* was the most common microorganism associated with fever (46.8% in febrile; 23.4% in afebrile people $p<0.001$). Bacteraemia was detected in 21.7% of febrile people and 12.7% of afebrile people ($p=0.001$). *Streptococcus pneumoniae* was the main cause of bacteraemia (7.1% of febrile and 0.6% of afebrile individuals; $p<0.001$). Non-typhoidal *Salmonella* spp. was detected in 4.5% of febrile people and 1.2% of afebrile individuals ($p<0.001$). *Salmonella enterica* Typhi and *S. enterica* Paratyphi were only detected in febrile subjects (1.4% and 2.1%), as well as *Tropheryma whipplei* (0.9%), *Streptococcus pyogenes* (0.7%), and *Plasmodium ovale* (4.6%). The prevalence in febrile and afebrile people was similar for *Staphylococcus aureus* (3.6-4.9%), *Rickettsia felis* (5.5-6.4%), *Mansonella perstans* (3.0-3.2%), and *Plasmodium malariae* (1.6-2.3%). Comorbidities were higher in febrile than in afebrile subjects (10.3% versus 5.5%; $p=0.01$); 82% involving *P. falciparum*. All patients co-infected with *P. falciparum* and *S. pneumoniae* were febrile whereas 30.0% of those infected by *P. falciparum* alone were not ($p=0.02$). Among febrile participants, 30.4% with malaria and 54.7% with bacteraemia had received neither antimalarial nor antibiotic therapy.

Conclusion: Identification of etiologies of acute febrile diseases in sub-Saharan Africa proposes keys to successful treatment and prevention of infectious diseases. Vaccination campaigns may decrease the morbidity of mono- and co-infections by preventable microorganisms.

1. Introduction

Despite a substantial decrease in malaria burden in several areas of sub-Saharan Africa [1–3], there is a lack of knowledge around non-malaria febrile illnesses in many countries in this area. In addition, the overlapping of clinical signs between malaria and other febrile illnesses makes differential diagnosis of fever difficult in resource-limited settings [4,5]. The establishment of the local epidemiology of fever aetiologies is critical in order to optimise the management of febrile patients and to ensure a better use of available drugs.

The burden of bacterial aetiologies is poorly understood. Traditional diagnostic tools, such as blood cultures, are available almost exclusively in large cities. Furthermore, blood cultures do not allow the isolation of intracellular or highly fastidious bacteria. Only common bacteria such as *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Salmonella* spp. are regarded as the main bacterial aetiologies of fever [6,7]. Recently, molecular strategies for the characterisation of bacterial bloodstream infections enabled to highlight the implication of fastidious bacteria such as *Rickettsia felis* and *Tropheryma whippelii* in Senegal and Gabon [8,9].

In Côte d'Ivoire between 1996 and 1998, studies investigating bacteraemia among febrile HIV-infected patients identified non-typhoidal *Salmonella enterica* (15), *S. pneumoniae* (13), *Escherichia coli* (6), *Shigella* spp. (2), *S. aureus* (2), *Proteus mirabilis* (1), and *Salmonella enterica* Typhi (1) as bacterial aetiologies [10]. More recently, between 2012 and 2014, after a long period when culture equipment was unavailable, a study on the morbidity related to bacterial blood infections was conducted in Bouaké (central Côte d'Ivoire) with *Klebsiella pneumoniae* and *S. enterica* being involved in 94% of bloodstream infections followed by *S. aureus* [11].

Although there is evidence of the circulation of zoonotic bacteria such as *C. burnetii*, *Rickettsia* spp., *Borrelia* spp., and *Anaplasma* spp. in cattle, sheep, goats, and ticks in Côte d'Ivoire [12,13], their role in human febrile illness has not yet been thoroughly investigated.

Our study, therefore, aimed to determine the burden of malaria, Mansonellosis, common and fastidious bacteria in Yamoussoukro (Côte d'Ivoire) using specific molecular tools and to compare the accuracy of treatments prescribed in the hospital and the retrospective molecular diagnosis.

2. Material and methods

2.1. Ethics statement

The Côte d'Ivoire National Research Ethics Committee and the Wale Hospital of Yamoussoukro (agreement number 86 MSLS / CNER-dkn) approved the study protocol. Written informed consent was obtained from each adult subject and from the parents or legal guardians of children included in the study.

2.2. Study site

The study was carried out at the Wale hospital in Yamoussoukro in Côte d'Ivoire (West Africa). Yamoussoukro is the political and administrative capital of the country and is located 248 km north of Abidjan, the economic capital (Figure 1). In the district, the vegetation is dominated by wet savanna with varying small trees. This area is characterised by its mean temperature of 26°C and the rainy season peaks between March-July, and September-October. The district of Yamoussoukro has a total of 362,000 inhabitants, of whom 199,100 (55%) live in urban areas.

2.3. Study population and sample collection

This is a cross-sectional epidemiological study. Between September 2014 and April 2015, 438 people consulting at the hospital for fever (axillary temperature $\geq 37.5^{\circ}\text{C}$) were recruited as well as comparative group of 346 asymptomatic people recruited at the same time. The afebrile comparative group consisted of asymptomatic volunteers, parents and children accompanying people seeking medical care, and who did not have episodes of fever in the previous month.

Three drops of blood from each participant (about 200 μL) were collected using the finger prick method and collected in an Eppendorf tube containing 20 μL of citrate. On site, DNA was extracted with QIAamp DNA kit (Qiagen, Hilden, Germany) in line with the manufacturer's protocol without elution. The columns of DNA were stored in the refrigerator before being transferred to the Institut Hospitalo-Universitaire Méditerranée Infection (Marseille, France), where DNA elution was performed with 200 μL of buffer AE (Acetone, EDTA). DNA was stored at $+4^{\circ}\text{C}$ until used for PCR analysis.

2.4. Assessment of DNA quality and molecular analysis

DNA quality was assessed using quantitative real-time PCR (qPCR) targeting the human β -actin gene, as previously reported [14]. After verifying the quality of DNA extracts, they were screened for the presence of *Plasmodium* spp., *S. pneumoniae*, *Staphylococcus aureus*, *Salmonella* spp., *S. pyogenes*, *Rickettsia* spp., *Borrelia* spp., *T. whipplei*, *C. burnetii*, *Bartonella* spp., *Leptospira* spp., *Anaplasma* spp., and *Mansonella* spp. using qPCR. The primers and probes used for each of the targeted microorganisms are presented in Table S1.

The final reaction volume (20 μL) of qPCR contained 10 μL of Master mix No ROX (Eurogentec, Liege, Belgium), 3.5 μL of distilled water (DNAase/RNAase free), 2.5 μM of probe, 20 μM of each primer, and 5 μL DNA. All reactions were carried using a CFX 96 (Bio-Rad, Marnes-la-Coquette, France) according to following settings: DNA denaturation steps at 50°C for 2 min and 95°C for 5 min followed by 40 cycles of one second at 95°C , 35

seconds at 60°C, and an extension step for 30 seconds at 45°C. In each reaction, two positive controls (DNA of targeted microorganism) and two negative controls (mix alone) were used to validate each PCR assay.

2.5. Statistical analysis

Statistical analyses were performed using SAS university edition software (version 9.4, SAS Institute Inc., Cary, NC, USA) and R software (version 3.6.2). Chi-square's and Fischer's tests were used to compare frequencies between febrile and afebrile subjects. For statistical significance, the two-sided *p. values* were set at 0.005. Principal Component Analysis (PCA) was performed to assess the relationship between relevant pathogens, demographic characteristics, fever, and other clinical signs.

3. Results

The average age of study participants was 20+/-12-year-old (range 3 weeks to 71 years old). Three hundred and forty-four febrile patients were urban residents and 94 came from rural areas.

The quality of the DNA extracted from all blood samples was satisfactory, given that the cycle threshold values (Ct) of qPCR targeting human β -actin gene ranged from 19 to 26. The demographic and clinical characteristics of the population studied are summarised in Table 1. Principal Component Analysis showed that *P. falciparum* and *S. pneumoniae* were strongly correlated with febrile status, asthenia, cough, rhinorrhoea, headaches, vomiting, and nausea (Figure 2). Otherwise, non-typhoidal *Salmonella*, *S. enterica* Paratyphi, diarrhoea, and abdominal pain were strongly correlated.

3.1. Parasitaemia

3.1.1. Malaria

Plasmodium parasites were the more frequently detected microorganisms with an overall prevalence of 38.5% (302/784). They were also significantly higher in febrile (49.5%, 217/438) than in afebrile subjects (24.6%, 85/346; $p<0.001$) (Table 2). Among febrile patients, *P. falciparum* was more frequently detected in rural (62.1%, 72/116) than in urban subjects (45%, 145/322; $p<0.001$), while no statistical differences were observed between rural and urban areas for *P. ovale* and *P. malariae* (Table 2). *P. falciparum* represented 94.7% (286/302) of samples which were positive for *Plasmodium* species. Its prevalence was significantly higher in febrile (46.8%, 205/438) than in afebrile subjects (23.4%, 81/346; $p<0.0001$). *P. ovale* was only identified in febrile patients (4.6%, 20/438). *P. malariae* was less common in febrile patients (1.6%, 7/438) than in afebrile subjects (2.3%, 8/346; $p=0.468$). In febrile people, the prevalence of malaria due to *P. falciparum* decreased with age ($p<0.001$) (Figure 3, Table 3). For *P. malariae* and *P. ovale*, no statistical differences were observed between age groups (Table 3).

3.1.2. *Mansonella perstans*

Filariasis due to *M. perstans* was detected in 3.1% (20/784) of subjects, including 3.0% (13/438) of febrile and 3.2% (11/346; $p=0.865$) of afebrile individuals (Figure 3). In febrile patients, the prevalence of *M. perstans* was significantly higher among those living in rural areas (6%, 7/116) as opposed to urban areas (1%, 6/322; $p=0.023$). The prevalence of *M. perstans* also increased significantly with age in febrile subjects (Table 3).

3.2. Bacteraemia

Overall, 21.7% of febrile people (95/438) had bacteraemia versus 12.7% of afebrile people (44/346; $p=0.001$). *S. pneumoniae* was the second most frequently detected microorganism, detected in 4.2% (33/784) of positive subjects. The prevalence of *S. pneumoniae* was significantly higher in febrile people (7.1%, 31/438) than in afebrile people (0.6%, 2/346; $p<0.001$). No significant difference was observed between febrile people living

in urban or rural areas (Table 2). In febrile people, *S. pneumoniae* was more frequently detected in children under five years old (15.1%, 19/126), followed by the 5-20 year old age group (2.4%, 3/123) and finally those aged over the age of 20 (4.8%, 9/189; $p=0.0003$) (Table 3). The two afebrile people who were positive for *S. pneumoniae* were 22 and 23 years old.

Salmonella spp. was more frequently identified in febrile subjects (7.5%, 33/438) than in afebrile subjects (1.2%, 4/346, $p<0.001$). Non-typhoidal *Salmonella* was identified only in afebrile people (1.2%, 4/346) but was significantly associated with fever ($p<0.001$). Indeed, non-typhoidal *Salmonella* was the most frequently detected species in febrile subjects (4.5%, 18/438), followed by *Salmonella enterica* Paratyphi (2.1%, 9/438), and *Salmonella enterica* Typhi (1.4%, 6/438). No significant difference was observed between febrile people living in rural and urban areas for non-typhoidal *Salmonella*. and *S. enterica* Paratyphi (Table 2) while *S. enterica* Typhi was significantly higher in rural areas (3.5%, 4/116) compared to urban areas (0.6%, 2/322; $p=0.045$). For non-typhoidal *Salmonella* and *S. enterica* Paratyphi, no statistical difference was observed between age groups, whereas *S. enterica* Typhi was only observed in children under the age of five (4.8%, 6/126; $p=0.001$).

S. aureus was detected in 4.2% (33/784) of subjects, more precisely in 3.6% (16/438) of febrile people and 4.9% of afebrile people (17/346, $p=0.383$). No statistical difference was observed according to location or age. *S. pyogenes* was only detected in three febrile children under the age of five (Table 3).

The prevalence of *R. felis* was 5.9% (46/784) among all individuals, of whom 5.5% were febrile (24/438) and 6.4% were afebrile (24/364, $p=0.603$). Its prevalence in febrile patients was significantly higher in rural areas (10.3%, 12/322) than in urban areas (3.7%, 12/322; $p=0.007$). *T. whipplei* was only identified in four febrile children under the age of eight, all of whom lived in an urban area.

3.3. Co-infections

Co-infections were significantly higher in febrile patients (10.3%, 45/438) than in afebrile people (5.5%, 19/346; $p=0.010$). Most of the co-infections involved *Plasmodium falciparum* (82.8%, 53/64). In addition, of the 286 patients who tested positive for *P. falciparum*, the probability of being febrile was significantly higher in patients co-infected with *S. pneumoniae* (12/12, 100%) than in mono-infected patients (193/274, 70.0%; $p=0.020$) (Table S2). Details of co-infections are summarised in Table 4.

3.4. Treatment prescribed at hospital and retrospective molecular diagnostic

Treatments prescribed at the hospital were compared to retrospective molecular diagnosis. Of the 95 patients with bacteraemia, 52 did not received antibiotic treatment. Of them, 15 were infected with *R. felis*, 10 with *S. pneumoniae*, 7 with non-typhoidal *Salmonella*, 6 with *S. aureus*, 3 with *S. enterica* Paratyphi, one with *S. enterica* Typhi, and one with *S. pyogenes*. Nine of the 52 patients who did not receive an antibiotic prescription had a mixed bacterial infection. One of them were co-infected with *R. felis* and *S. aureus*, one with *R. felis* and non-typhoidal *Salmonella*, 3 three with *S. aureus* and *S. pneumoniae*, one with *S. pyogenes* and *S. aureus*, one with *S. pyogenes* and *S. enterica* Typhi, and 2 with *T. whipplei* and *S. pneumoniae*. Forty-three of the 95 patients with bacteraemia received antibiotics. Retrospective molecular diagnosis of bacteraemia and antibiotics prescribed when febrile patients were admitted to hospital are summarised in Table 5. Conversely, 133 of 343 patients without bacteraemia linked with screened bacteria received antibiotics (39 combinations of amoxicillin and clavulanic acid, 35 amoxicillin, one combination of amoxicillin, clavulanic acid and ampicillin, 11 cefadroxil, 12 cefpodoxime, 3 azithromycin, 16 ciprofloxacin, one enrofloxacin, 2 erythromycin, one flucloxacillin, one imidazole, and 11 metronidazole).

Overall, 66 of the 217 febrile patients (30.4%) who were positive for *Plasmodium* spp. did not received antimalarial drugs (Figure 4). Of these, 56 were infected with *P. falciparum* alone, 2 two with *P. falciparum* and *P. malariae*, 3 with *P. malariae* alone, and 5 with *P.*

225 *ovale* alone. Conversely, 116 (52.5%) of patients without malaria received antimalarial drugs
226 (Figure 4). Of these, 109 received artemether-lumefantrine, one received artesunate-
227 amodiaquine, 3 quinine, 2 sulfadoxine-pyrimethamine, and one received piperaquine.

229 4. Discussion

231 Malaria is the main aetiology in patients consulting for fever at the Wale Hospital in
232 Yamoussoukro, with *P. falciparum* being the most frequently identified species. Previous
233 studies in Côte d'Ivoire were performed using the thick smear procedure, which is known to
234 be less sensitive than molecular tools. In 2008, the prevalence of malaria at the Abobo
235 Hospital in Abidjan was estimated at 29.5% among 902 febrile people and 13.5% among 681
236 afebrile people [15]. However, in the town of Tabou in 2010 and 2011 the prevalence of
237 malaria was estimated at between 55.1% of 147 and 67.1% of 158 febrile people, and between
238 45% of 948 to 56.8% of 1,029 afebrile people, respectively) [16]. In addition to the difference
239 of sensitivity of each tool, geographic differences could explain the disparity of malaria
240 prevalence, as Yamoussoukro alternates between forest and savannah [17] while Abobo is in
241 a plateau area and Tabou is predominantly equatorial forest. Overall, a high rate of
242 asymptomatic malaria was observed, as has been reported in other countries with high malaria
243 transmission [18,19]. This high number of asymptomatic infections poses a challenge to
244 malaria elimination efforts [20]. Finally, malaria was more prevalent among younger people
245 and in rural areas, as previously reported [1,16,21–24]. The prevalence of *M. perstans* was
246 similar in febrile and afebrile subjects. Indeed, *M. perstans* is quite often asymptomatic in
247 populations in endemic areas [25]. Conversely, *M. perstans* may be responsible for invasive
248 infections for people from non-endemic areas coming to endemic areas in Africa or America
249 [25,26]. As already observed, *M. perstans* is significantly more common among adult and

rural populations [27,28].

Bacteraemia was found in 21.7% of patients, with *S. pneumoniae* being the leading aetiological agent and strongly associated with fever. A first study on the morbidity of bloodstream infections, conducted using blood cultures between 2012 and 2014 in Côte d'Ivoire, found similar bacteraemia rates (22.5%, 293) but did not find *S. pneumoniae* [11]. Nevertheless, based on a previous study carried out in Côte d'Ivoire between 1999 and 2013, on aetiologies of meningitis among children, *S. pneumoniae* was responsible for 44% of meningitis cases [29]. Although *S. pneumoniae* is the main cause of febrile bacteraemia, no fatal cases were observed in our study.

S. enterica Typhi and Paratyphi were only observed in febrile people while non-typhoidal *Salmonella*, although significantly more prevalent in febrile people, was also detected in afebrile people. In addition, just over half of the people infected with non-typhoid *Salmonella* were co-infected with *P. falciparum*. A positive correlation between *Salmonella* bacteraemia and malaria has been reported for a long time [30].

Although *S. aureus* has already been reported as a main cause of community acquired bloodstream infections in Africa [31], its prevalence was similar in febrile and afebrile subjects. Asymptomatic carriage of *S. aureus* is common in humans [32,33]. Thus, contamination by skin microbiota during blood sampling should be mentioned. However, asymptomatic *S. aureus* bacteraemia, by analogy with asymptomatic malaria, cannot be fully excluded. Finally, *S. pyogenes* was only very rarely observed and only in febrile children.

R. felis was already detected in one *Ctenocephalides canis* collected from a dog in Bouaké, Côte d'Ivoire [34]. However, to the best of our knowledge, this is the first report of *R. felis* bacteraemia in this country. *R. felis* bacteraemia has already been reported in west Africa (Senegal), central Africa (Gabon), and east Africa (Kenya) mainly in febrile people but also in afebrile people [8,35,36]. In Gabon, in the rural area of Fougamou, its prevalence

reached 39.7% (23/58) in febrile children, compared to 5.0% (1/20) in afebrile children in the same area and 1.3% (1/77) in febrile children in the city of Franceville [8]. In our study, no difference was observed between febrile and afebrile people, but the prevalence of *R. felis* bacteraemia was significantly higher in rural areas. Finally, *R. felis* was also detected in Senegal in skin swabs from eschars in acute febrile patients and healthy villagers, but not in those of French urban residents [35,37].

To the best of our knowledge, this is also the first report in Côte d'Ivoire of *T. whipplei*, the agent of Whipple's disease [38]. In rural Africa, *T. whipplei* has already been detected in faeces, mainly from young, asymptomatic and diarrhoeic children in Gabon, Ghana and Senegal [39–41]. Acute *T. whipplei* bacteraemia has also been reported in febrile people in rural areas of Senegal, including in young children presenting with a cough, but also as a cause of epidemic fever [42,43], and in a child from Lastoursville in rural Gabon [44,45].

Co-infections between malaria and bacterial bloodstream infections, mainly due to non-typhoid *Salmonella*, are commonly described in sub-Saharan Africa in febrile people and are associated with an increased risk of poor prognosis [46,47]. Surprisingly, for the first time we report a co-infection between *P. falciparum* and non-typhoid *Salmonella* in 3 afebrile children who had not experienced fever nor taken antibiotic or antimalarial treatment in the previous month. Of course, the molecular analysis used to screen for pathogens cannot provide any information on the viability of these microorganisms but the persistence of bacterial DNA in the blood has never been reported for acute infections, to the best of our knowledge. In addition, it should be noted that all patients co-infected with *S. pneumoniae* and *P. falciparum* were febrile. This suggests the further necessity to evaluate the efficacy of the vaccination against *S. pneumoniae* for the prevention febrile episodes linked to malaria.

The differences between the retrospective molecular diagnosis and the anti-infectives prescribed for hospital admission in febrile patients can easily be explained by the lack of

reliable diagnostic tools available. A Ghanaian study found that 4.5% of the 247 children with a retrospectively confirmed diagnosis of malaria had not received antimalarial drugs, while up to 84.1% of the 446 children without malaria had received antimalarial drugs [48]. It is likely that the inappropriate use of anti-infectives is still common practice in sub-Saharan Africa. Indeed, the diversity of infectious aetiologies, the presence of co-infections, the prevalence of asymptomatic infections, the few or complete lack of diagnostic tools make the therapeutic choices available to physicians very difficult. Current WHO recommendations for the management of fever in sub-Saharan Africa are to identify signs of severity in patients with fever. If there are signs of seriousness, antimalarials and antibiotics are automatically prescribed before admission. After admission, rapid diagnostic testing for malaria and blood film are performed. If at least one test is positive, parenteral antimalarials should be given, and in other cases parenteral antibiotics should be administered before assessing for other causes of fever. If there is no sign of severity, a rapid malaria diagnostic test and a blood smear should be performed, and if at least one of them is positive, antimalarial treatments should be administered. In other cases, an antimalarial treatment should be prescribed and the patient must be monitored before trying to identify another cause of fever [49].

Improving the management of febrile illnesses in sub-Saharan Africa requires effort and resources that go beyond the deployment of rapid malaria tests. Indeed, it is also necessary to understand the repertoire of bacteria present in the ecosystems of the different regions in order to simultaneously answer the question that if it is not malaria, then what can it be, and which empirical antibiotic therapy would be the most appropriate. Although our study has some limitations (lack of traditional blood cultures and lack of data about antibiotic susceptibility, differences in age/sex in febrile group of patients and comparative afebrile group, lack of data on RNA viruses as causative agents due to the logistic difficulties for the RNA conservation), it highlights the persistent presence of such pathogenic microorganisms as *S. pneumoniae* and

325 *S. enterica* Typhi as well as possible association between co-infection *S. pneumoniae*/malaria
326 with acute febrile episodes. Vaccines against these bacteria are available, so, vaccination
327 campaigns in sub-Saharan Africa may decrease acute febrile morbidity associated with these
328 preventable microorganisms.
329

References

1. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. *Lancet* 2013;382:900–11. doi:10.1016/S0140-6736(13)60310-4
2. Kouassi BL, de Souza DK, Goepogui A, Balde SM, Diakité L, Sagno A, et al. Low prevalence of *Plasmodium* and absence of malaria transmission in Conakry, Guinea: prospects for elimination. *Malar J* 2016;15:175. doi:10.1186/s12936-016-1230-9
3. WHO | World Malaria Report 2013. Available: https://www.who.int/malaria/publications/world_malaria_report_2013/en/
4. Chipwaza B, Mhamphi GG, Ngatunga SD, Selemani M, Amuri M, Mugasa JP, et al. Prevalence of bacterial febrile illnesses in children in Kilosa district, Tanzania. *PLoS Negl Trop Dis* 2015;9:e0003750. doi:10.1371/journal.pntd.0003750
5. Chipwaza B, Mugasa JP, Mayumana I, Amuri M, Makungu C, Gwakisa PS. Community knowledge and attitudes and health workers' practices regarding non-malaria febrile illnesses in eastern Tanzania. *PLoS Negl Trop Dis* 2014;8:e2896. doi:10.1371/journal.pntd.0002896
6. Msemu OA, Mbwana J, Mahende C, Malabeja A, Gesase S, Crump JA, et al. Epidemiology and antimicrobial susceptibility of *Salmonella enterica* bloodstream isolates among febrile children in a rural district in Northeastern Tanzania: A Cross-sectional study. *Clin Infect Dis* 2019;68:S177–S182. doi:10.1093/cid/ciy1126
7. Msefula CL, Olgemoeller F, Jambo N, Segula D, Van Tan T, Nyirenda TS, et al. Ascertaining the burden of invasive *Salmonella* disease in hospitalised febrile children aged under four years in Blantyre, Malawi. *PLoS Negl Trop Dis* 2019;13:e0007539. doi:10.1371/journal.pntd.0007539
8. Mourembou G, Lekana-Douki JB, Mediannikov O, Nzondo SM, Kouna LC, Essone

355 JCBB, et al. Possible role of *Rickettsia felis* in acute febrile illness among children in Gabon.
356 Emerg Infect Dis 2015;21:1808–15. doi:10.3201/eid2110.141825

357 9. Sokhna C, Mediannikov O, Fenollar F, Bassene H, Diatta G, Tall A, et al. Point-of-
358 care laboratory of pathogen diagnosis in rural Senegal. PLoS Negl Trop Dis 2013;7:e1999.
359 doi:10.1371/journal.pntd.0001999

360 10. Anglaret X, Dakoury-Dogbo N, Bonard D, Touré S, Combe P, Ouassa T, et al. Causes
361 and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Côte d’Ivoire.
362 AIDS 2002;16:909–18. doi: 10.1097/00002030-200204120-00011

363 11. Akoua-Koffi C, Tia H, Plo JK, Monemo P, Cissé A, Yao C, et al. Epidemiology of
364 community-onset bloodstream infections in Bouaké, central Côte d’Ivoire. New Microbes
365 New Infect 2015;7:100–4. doi:10.1016/j.nmni.2015.06.009

366 12. Ehounoud CB, Yao KP, Dahmani M, Achi YL, Amanzougaghene N, Kacou N’Douba
367 A, et al. Multiple pathogens including potential new species in tick vectors in Côte d’Ivoire.
368 PLoS Negl Trop Dis 2016;10:e0004367. doi:10.1371/journal.pntd.0004367

369 13. Kanouté YB, Gragnon BG, Schindler C, Bonfoh B, Schelling E. Epidemiology of
370 brucellosis, Q Fever and Rift Valley Fever at the human and livestock interface in northern
371 Côte d’Ivoire. Acta Trop 2017;165:66–75. doi:10.1016/j.actatropica.2016.02.012

372 14. Mediannikov O, Fenollar F, Socolovschi C, Diatta G, Bassene H, Molez JF, et al.
373 *Coxiella burnetii* in humans and ticks in rural Senegal. PLoS Negl Trop Dis 2010;4:e654.
374 doi:10.1371/journal.pntd.0000654

375 15. Assoumou A, Adoubryn KD, Aboum KS, Kouadio-Yapo CG, Ouhon J. Symptomatic
376 and asymptomatic *Plasmodium falciparum* infection in children from 6 months to 6 years old
377 in the Abobo general hospital (Abidjan, Côte d’Ivoire). Bull Soc Pathol Exot 2008;101:50–3.

378 16. Bassa FK, Ouattara M, Silué KD, Adiossan LG, Baikoro N, Koné S, et al.
379 Epidemiology of malaria in the Taabo health and demographic surveillance system, south-

380 central Côte d'Ivoire. *Malar J* 2016;15. doi:10.1186/s12936-015-1076-6

381 17. Konan E, Yaokokore-Beibro H. Variation temporelle du peuplement aviaire des
382 écosystème lacustres de la ville de Yamoussoukro, centre de la Côte d'Ivoire. *Int J Biol Chem*
383 *Sci* 2016;9:2566.

384 18. Sattabongkot J, Suansomjit C, Nguitragool W, Sirichaisinthop J, Warit S, Tiensuwan
385 M, et al. Prevalence of asymptomatic *Plasmodium* infections with sub-microscopic parasite
386 densities in the northwestern border of Thailand: a potential threat to malaria elimination.
387 *Malar J* 2018;17. doi:10.1186/s12936-018-2476-1

388 19. Nkoghe D, Akue JP, Gonzalez JP, Leroy EM. Prevalence of *Plasmodium falciparum*
389 infection in asymptomatic rural Gabonese populations. *Malar J* 2011;10:33.
390 doi:10.1186/1475-2875-10-33

391 20. Sattabongkot J, Suansomjit C, Nguitragool W, Sirichaisinthop J, Warit S, Tiensuwan
392 M, et al. Prevalence of asymptomatic *Plasmodium* infections with sub-microscopic parasite
393 densities in the northwestern border of Thailand: a potential threat to malaria elimination.
394 *Malar J* 2018;17:329. doi:10.1186/s12936-018-2476-1

395 21. Assele V, Ndoh GE, Nkoghe D, Fandeur T. No evidence of decline in malaria burden
396 from 2006 to 2013 in a rural Province of Gabon: implications for public health policy. *BMC*
397 *Public Health* 2015;15. doi:10.1186/s12889-015-1456-4

398 22. Mourembou G, Nzondo SM, Ndjoyi-Mbiguino A, Lekana-Douki JB, Kouna LC,
399 Matsiegui PB, et al. Co-circulation of *Plasmodium* and Bacterial DNAs in blood of febrile
400 and afebrile children from urban and rural areas in Gabon. *Am J Trop Med Hyg* 2016;95:
401 123–32. doi:10.4269/ajtmh.15-0751

402 23. Nankabirwa J, Zurovac D, Njogu JN, Rwakimari JB, Counihan H, Snow RW, et al.
403 Malaria misdiagnosis in Uganda – implications for policy change. *Malar J* 2009;8:66.
404 doi:10.1186/1475-2875-8-66

- 405 24. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al.
406 Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective
407 study. *BMJ* 2004;329:1212. doi:10.1136/bmj.38251.658229.55
- 408 25. Simonsen PE, Onapa AW, Asio SM. *Mansonella perstans* filariasis in Africa. *Acta*
409 *Trop* 2011;120:S109–S120. doi:10.1016/j.actatropica.2010.01.014
- 410 26. Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB. Loiasis in Endemic
411 and nonendemic populations: Immunologically mediated differences in clinical presentation. *J*
412 *Infect Dis* 1991;163:1318–25. doi:10.1093/infdis/163.6.1318
- 413 27. Bassene H, Sambou M, Fenollar F, Clarke S, Djiba S, Mourembou G, et al. High
414 Prevalence of *Mansonella perstans* filariasis in rural Senegal. *Am J Trop Med Hyg* 2015;93:
415 601–6. doi:10.4269/ajtmh.15-0051
- 416 28. Mourembou G, Fenollar F, Lekana-Douki JB, Ndjoiy Mbiguino A, Maghendji
417 Nzondo S, Matsiegui PB, et al. *Mansonella*, including a potential new species, as common
418 parasites in children in Gabon. *PLoS Negl Trop Dis* 2015;9.
419 doi:10.1371/journal.pntd.0004155
- 420 29. Asse KV, Seka A, Poe P, Diabate C, Brou-Simonne, Plo KJ. Méningites bactériennes
421 de l'enfant au centre hospitalier universitaire de Bouaké en République de Côte d'Ivoire. *Arch*
422 *Pédiatrie* 2001;8:1266–7. doi:10.1016/S0929-693X(01)00641-8
- 423 30. Park SE, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, et al. The relationship
424 between invasive nontyphoidal *Salmonella* disease, other bacterial bloodstream infections,
425 and malaria in Sub-Saharan Africa. *Clin Infect Dis* 2016;62:S23–S31. doi:10.1093/cid/civ893
- 426 31. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in
427 Africa: a systematic review and meta-analysis. *Lancet Infect Dis* 2010;10:417–32.
428 doi:10.1016/S1473-3099(10)70072-4
- 429 32. Mediannikov O, Socolovschi C, Million M, Sokhna C, Bassene H, Diatta G, et al.

430 Molecular identification of pathogenic bacteria in eschars from acute febrile patients, Senegal.
 431 Am J Trop Med Hyg 2014;91:1015–9. doi: 10.4269/ajtmh.13-0629

432 33. Ndiaye C, Bassene H, Lagier JC, Raoult D, Sokhna C. Asymptomatic carriage of
 433 *Streptococcus pneumoniae* detected by qPCR on the palm of hands of populations in rural
 434 Senegal. PLoS Negl Trop Dis 2018;12:e0006945. doi: 10.1371/journal.pntd.0006945

435 34. Berrelha J, Briolant S, Muller F, Rolain JM, Marié JL, Pagés F, et al. *Rickettsia felis*
 436 and *Rickettsia massiliae* in Ivory Coast, Africa. Clin Microbiol Infect 2009;15:251–2.
 437 doi:10.1111/j.1469-0691.2008.02273.x

438 35. Socolovschi C, Mediannikov O, Sokhna C, Tall A, Diatta G, Bassene H, et al.
 439 *Rickettsia felis*–associated uneruptive fever, Senegal. Emerg Infect Dis 2010;16:1140–2.
 440 doi:10.3201/eid1607.100070

441 36. Richards AL, Jiang J, Omulo S, Dare R, Abdirahman K, Ali A, et al. Human infection
 442 with *Rickettsia felis*, Kenya. Emerg Infect Dis 2010;16:1081–6. doi:10.3201/eid1607.091885

443 37. Mediannikov O, Socolovschi C, Edouard S, Fenollar F, Mouffok N, Bassene H, et al.
 444 Common epidemiology of *Rickettsia felis* infection and malaria, Africa. Emerg Infect Dis
 445 2013;19:1775–83. doi:10.3201/eid1911.130361

446 38. Fenollar F, Lagier JC, Raoult D. *Tropheryma whippelii* and Whipple’s disease. J Infect
 447 2014;69:103–12. doi: 10.1016/j.jinf.2014.05.008

448 39. Keita AK, Bassene H, Tall A, Sokhna C, Ratmanov P, Trape JF, et al. *Tropheryma*
 449 *whippelii*: A common bacterium in rural Senegal. PLoS Negl Trop Dis 2011;5.
 450 doi:10.1371/journal.pntd.0001403

451 40. Vinnemeier CD, Klupp EM, Krumkamp R, Rolling T, Fischer N, Owusu-Dabo E, et
 452 al. *Tropheryma whippelii* in children with diarrhoea in rural Ghana. Clin Microbiol Infect
 453 2016;22:65.e1-65.e3. doi:10.1016/j.cmi.2015.09.022

454 41. Ramharter M, Harrison N, Bühler T, Herold B, Lagler H, Lötsch F, et al. Prevalence

455 and risk factor assessment of *Tropheryma whipplei* in a rural community in Gabon: a
 456 community-based cross-sectional study. Clin Microbiol Infect 2014;20:1189–94.
 457 doi:10.1111/1469-0691.12724

458 42. Fenollar F, Mediannikov O, Socolovschi C, Bassene H, Diatta G, Richet H, et al.
 459 *Tropheryma whipplei* bacteremia during fever in rural West Africa. Clin Infect Dis 2010;51:
 460 515–21. doi:10.1086/655677

461 43. Bassene H, Mediannikov O, Socolovschi C, Ratmanov P, Keita AK, Sokhna C, et al.
 462 *Tropheryma whipplei* as a cause of epidemic fever, Senegal, 2010–2012. Emerg Infect Dis
 463 2016;22:1229–34. doi:10.3201/eid2207.150441

464 44. Mourembou G, Fenollar F, Socolovschi C, Lemamy GJ, Nzoughe H, Kouna LC, et al.
 465 Molecular detection of fastidious and common bacteria as well as *Plasmodium* spp. in febrile
 466 and afebrile children in Franceville, Gabon. Am J Trop Med Hyg 2015;92:926–32. doi:
 467 10.4269/ajtmh.14-0699

468 45. Ramharter M, Harrison N, Bühler T, Herold B, Lagler H, Lötsch F, et al. Prevalence
 469 and risk factor assessment of *Tropheryma whipplei* in a rural community in Gabon: a
 470 community based cross-sectional study. Clin Microbiol Infect 2014;20:1189–94. doi:
 471 10.1111/1469-0691.12724

472 46. Church J, Maitland K. Invasive bacterial co-infection in African children with
 473 *Plasmodium falciparum* malaria: a systematic review. BMC Med 2014;12. doi:10.1186/1741-
 474 7015-12-31

475 47. Mtove G, Amos B, Von Seidlein L, Hendriksen I, Mwambuli A, Kimera J, et al.
 476 Invasive salmonellosis among children admitted to a rural Tanzanian hospital and a
 477 comparison with previous studies. PloS One 2010;5:e9244. doi:
 478 10.1371/journal.pone.0009244

479 48. Orish VN, Ansong JY, Onyeabor OS, Sanyaolu AO, Oyibo WA, Iriemenam NC.

480 Overdiagnosis and overtreatment of malaria in children in a secondary healthcare centre in
481 Sekondi-Takoradi, Ghana. Trop Doct 2016;46:191–98. doi:10.1177/0049475515622861
482 49. WHO | WHO informal consultation on fever management in peripheral health care
483 settings: A global review of evidence and practice. WHO 2013. Available:
484 <http://www.who.int/malaria/publications/atoz/9789241506489/en/>
485

Funding

The authors thank “l’Association Pour la Recherche en Infectiologie (APRI)” for funding some of the fieldwork. Our thanks also go to all those who agreed to take part in this study. We thank also the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, the French National Research Agency for supporting this study, under the “Investissements d’avenir” programme, reference ANR-10-IAHU-03, the Région Provence Alpes Côte d’Azur and European funding FEDER IHUBIOTK.

Declaration of competing interest

The authors report no potential conflicts.

Legends of figures and tables.

Figure 1. Map of the study site in Côte d’Ivoire.

Figure 2. Principal Component Analysis (PCA) of clinical and biological outcomes, demographic characteristics of 348 febrile patients and 346 afebrile people.

Figure 3. Prevalence of microorganisms detected among the 438 febrile patients according to age.

Figure 4. Rate of antimalarial (A) and antibiotic (B) prescriptions upon admission to hospital compared to retrospective molecular diagnostic outcomes.

Table 1. Demographic and clinical characteristics of the population studied.

Table 2. Prevalence of microorganisms detected in 438 febrile patients and 346 afebrile people (A) and their prevalence by geographic origin in febrile patients (B).

Table 3. Prevalence of microorganisms according to age group in febrile people.

Table 4. Prevalence of co-infections among 438 febrile and 346 afebrile people.

Table 5. Retrospective molecular diagnosis of bacteremia and respective antibiotic treatment prescribed at admission to hospital in febrile patients.




Figure 1. Map of the study site in Côte d'Ivoire.




Figure 2. Principal Component Analysis (PCA) of clinical and biological outcomes, demographic characteristics of 348 febrile patients and 346 afebrile people.




Figure 3. Prevalence of microorganisms detected among the 438 febrile patients according to age.




Figure 4. Rate of antimalarial (A) and antibiotic (B) prescriptions upon admission to hospital compared to retrospective molecular diagnostic outcomes.

Table 1. Demographic and clinical characteristics of the population studied.

	438 febrile patients	346 afebrile people
	Number (%)	
Male sex	176 (40.3)	201 (58.1)
Age group (years)		
<5	222 (50.8)	13 (3.8)
5-20	119 (27.2)	314 (90.7)
>20	96 (22.0)	19 (5.5)
Complaints		
Non-specific		
Headache	243 (55.5)	35 (10.1)
Asthenia	202 (46.1)	7 (2.0)
Rhinorrhea	73 (16.7)	0
Gastrointestinal symptoms	222 (50.7)	0
Vomiting	136 (31.1)	0
Nausea	130 (29.7)	0
Abdominal pain	62 (14.2)	0
Diarrhea	27 (6.2)	0
Respiratory symptoms	190 (43.4)	0
Cough	162 (37.0)	0
Expectoration	7 (1.6)	0
Dyspnea	23 (5.3)	0

Missing values for age (n = 1) and sex (n = 1) in febrile individuals.

Table 2. Prevalence of microorganisms detected in 438 febrile patients and 346 afebrile people (A) and their prevalence by geographic origin in febrile patients (B).

A.	438 febrile patients	346 afebrile people	
Microorganisms	Number of positive (%)		<i>p. value</i> *
Bacteria			
<i>S. pneumoniae</i>	31 (7.1)	2 (0.6)	<0.001
<i>R. felis</i>	24 (5.5)	22 (6.4)	0.603
Non-typhoidal <i>Salmonella</i>			
<i>enterica</i>	18 (4.5)	4 (1.2)	<0.001
<i>S. aureus</i>	16 (3.6)	17 (4.9)	0.383
<i>S. enterica</i> Paratyphi	9 (2.1)	0	0.005
<i>S. enterica</i> Typhi	6 (1.4)	0	0.030
<i>T. whipplei</i>	4 (0.9)	0	0.134
<i>S. pyogenes</i>	3 (0.7)	0	0.259
Parasites			
<i>Plasmodium</i> spp.	217 (49.5)	85 (24.6)	<0.001
<i>P. falciparum</i>	205 (46.8)	81 (23.4)	<0.001
<i>P. ovale</i>	20 (4.6)	0	<0.001
<i>P. malariae</i>	7 (1.6)	8 (2.3)	0.468
<i>Mansonella perstans</i>	13 (3)	11 (3.2)	0.865
No samples were positive for <i>C. burnetii</i> , <i>Borrelia</i> spp., <i>Bartonella</i> spp., and <i>Leptospira</i> spp.			
* Significant <i>p. value</i> (<0.05) are in bold (Chi-square or Fisher's exact tests, 2-sided <i>p. values</i>).			

B.	322 febrile urban inhabitants	116 febrile rural inhabitants	
Microorganisms	Number of positive (%)		<i>p. value</i>
Bacteria			
<i>S. pneumoniae</i>	20 (6.2)	11 (9.5)	0.239
<i>R. felis</i>	12 (3.7)	12 (10.3)	0.007
Non-typhoidal <i>Salmonella</i>			
<i>enterica</i>	12 (3.7)	6 (5.2)	0.501
<i>S. aureus</i>	12 (3.7)	4 (3.5)	1.000
<i>S. enterica</i> Paratyphi	7 (2.2)	2 (1.7)	0.770
<i>S. enterica</i> Typhi	2 (0.6)	4 (3.5)	0.045
<i>T. whipplei</i>	4 (1.2)	0	0.500
<i>S. pyogenes</i>	2 (0.6)	1 (0.9)	1.000
Parasites			
<i>Plasmodium</i> spp.	145 (45.0)	72 (62.1)	<0.001
<i>P. falciparum</i>	135 (41.9)	70 (60.3)	0.007
<i>P. ovale</i>	15 (4.7)	5 (4.3)	0.878
<i>P. malariae</i>	3 (0.9)	4 (3.4)	0.064
<i>M. perstans</i>	6 (1.0)	7 (6.0)	0.023

Table 3. Prevalence of microorganisms according to age groups in febrile people.

	Age groups (Years)			
	<5	5 – 20	>20	
	Number of febrile people			
	126	123	189	
Microorganisms	Number of positive (%)			<i>p. value*</i>
Bacteria				
<i>S. pneumoniae</i>	19 (15.1)	3 (2.4)	9 (4.8)	0.003
<i>R. felis</i>	7 (5.6)	7 (5.7)	10 (5.3)	0.999
Non-typhoidal <i>Salmonella enterica</i>	6 (4.8)	4 (3.3)	8 (4.2)	0.869
<i>S. aureus</i>	8 (6.4)	5 (4.1)	3 (1.6)	0.075
<i>Salmonella enterica</i> Paratyphi	2 (1.6)	4 (3.3)	3 (1.6)	0.632
<i>Salmonella enterica</i> Typhi	6 (4.8)	0	0	0.001
<i>T. whipplei</i>	3 (2.4)	1 (0.8)	0	0.064
<i>S. pyogenes</i>	3 (2.4)	0	0	0.045
Parasites				
<i>P. falciparum</i>	74 (58.7)	69 (56.1)	62 (32.8)	<0.001
<i>P. ovale</i>	7 (5.6)	9 (7.3)	4 (2.1)	0.064
<i>P. malariae</i>	2 (1.6)	0	5 (2.7)	0.215
<i>M. perstans</i>	1 (0.8)	1 (0.6)	12 (6.4)	0.001

* Significant *p. value* (<0.05) are in bold (Chi-square or Fisher's exact tests, 2-sided *p. value*).

Table 4. Prevalence of co-infections among 438 febrile and 346 afebrile people.

	438 febrile patients 346 afebrile people		
	Number of positive (%)		p. value
Co-infections	45 (10.3%)	19 (5.5%)	0.01
Triple infections	8 (1.8%)	2 (0.6%)	0.100
<i>P. falciparum</i> / <i>M. perstans</i> / Non-typhoidal <i>Salmonella</i>	0	1 (0.3)	0.441
<i>P. falciparum</i> / <i>P. malariae</i> / <i>S. aureus</i>	0	1 (0.3)	0.441
<i>P. falciparum</i> / <i>P. malariae</i> / <i>S. pneumoniae</i>	1 (0.2)	0	0.999
<i>P. falciparum</i> / <i>P. ovale</i> / <i>R. felis</i>	1 (0.2)	0	0.999
<i>P. falciparum</i> / <i>P. ovale</i> / <i>S. aureus</i>	2 (0.5)	0	0.506
<i>P. falciparum</i> / <i>R. felis</i> / <i>S. aureus</i>	1 (0.2)	0	1.000
<i>P. falciparum</i> / <i>S. aureus</i> / <i>S. pneumoniae</i>	2 (0.5)	0	0.506
<i>P. ovale</i> / <i>S. aureus</i> / <i>S. enterica</i> Typhi	1 (0.2)	0	0.999
Double infections	37 (8.5%)	17 (4.9%)	0.05
<i>P. falciparum</i> / <i>M. perstans</i>	2 (0.5)	3 (0.9)	0.659
<i>P. falciparum</i> / <i>R. felis</i>	8 (1.8)	6 (1.7)	0.922
<i>P. falciparum</i> / <i>S. aureus</i>	10 (2.3)	3 (0.9)	0.162
<i>P. falciparum</i> / Non-typhoidal <i>Salmonella</i>	10 (2.3)	2 (0.6)	0.077
Non-typhoidal <i>Salmonella</i> / <i>M. perstans</i>	2 (0.5)	1 (0.3)	0.999
Non-typhoidal <i>Salmonella</i> / <i>T. whipplei</i>	2 (0.5)	0	0.999
<i>R. felis</i> / <i>S. aureus</i>	1 (0.2)	1 (0.3)	0.999
<i>R. felis</i> / Non-typhoidal <i>Salmonella</i>	1 (0.2)	0	0.999
<i>R. felis</i> / <i>S. enterica</i> Typhi	1 (0.2)	0	0.999
<i>R. felis</i> / <i>M. perstans</i>	0	1 (0.3)	0.441

Table 5. Retrospective molecular diagnosis of bacteremia and respective antibiotic treatment prescribed at admission to hospital in febrile patients.

Retrospective molecular diagnosis	Antibiotic treatment at admission	Number of patients
<i>S. pneumoniae</i>	Amoxicillin	8
	Amoxicillin and clavulanic acid	1
	Amoxicillin / Metronidazole	1
	Cefadroxil	2
	Rifamycin / Enrofloxacin/ Cefpodoxime	1
	Cefadroxil / Ethambutol	1
<i>R. felis</i>	Amoxicillin	2
	Cefadroxil	1
	Neomycin / Bacitracin	1
	Metronidazole	1
	Penicillin	1
<i>S. enterica</i> Typhi	Amoxicillin and clavulanic acid	3
	Cefadroxil	2
	Nifuroxazide	1
	Amoxicillin and clavulanic acid	1
Non-typhoidal <i>Salmonella</i> spp.	Amoxicillin	4
	Azythromycin	1
	Amoxicillin and clavulanic acid	3
<i>S. enterica</i> Paratyhi / <i>S. aureus</i>	Amoxicillin	1
	Amoxicillin and clavulanic acid	1
<i>S. aureus</i> / <i>S. pneumoniae</i>	Amoxicillin	1
	Cefadroxil	1
<i>S. enterica</i> Paratyhi	Amoxicillin	1
<i>S. aureus</i>	Flucloxacillin	1
<i>R. felis</i> / <i>S. enterica</i> Typhi	Cefadroxil	1
<i>T. whipplei</i> / non-typhoidal <i>Salmonella</i> spp.	Amoxicillin and clavulanic acid	1